AI Summary
✦ ClarthaValuation Metrics
Trading 217.0% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +3.34). Confidence: 52%.
Live forward EPS implies next-12-month EPS of ₹28.68. Applying the stock's normalized valuation corridor produces a fair range of ₹605.43 to ₹1,342.22, with base value near ₹822.54 (-55.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹28.68
Forward P/E
64.6x
Base Fair Value
₹822.54
Fair Range
₹605.43 - ₹1,342.22
Upside To Base
-55.6%
Estimate Source
Live forward EPS
Growth Estimate
+125.2%
5Y Average
31.15
Current
90.90
Overvalued
46.80
Undervalued
21.11
5Y Average
17.14
Current
50.28
Overvalued
17.34
Undervalued
11.15
5Y Average
4.70
Current
13.78
Overvalued
4.75
Undervalued
3.06
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +95% vs avg | +36.2% |
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Fair | -13% vs avg | -2.7% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -53% vs avg | +21.5% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Premium | +22% vs avg | +0.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Fair | -12% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -6% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -4% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -28% vs avg | -3.9% |
LAURUS LABS LIMITED trades at a premium (91.4x vs peer avg 40.4x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include TORRENT PHARMACEUTICALS L, CIPLA LTD, LUPIN LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.76K CrJun 2026Latest net profit
₹290 CrJun 2026Latest EPS
₹5.37Jun 2026Net margin
28.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,108 | 1,158 | 1,132 | 1,415 | 1,117 | 1,185 | 1,265 | 1,650 | 1,433 | 1,567 | 1,509 | 1,580 | 1,757 |
| Expenses + | 980 | 978 | 962 | 1,143 | 956 | 1,003 | 1,059 | 1,255 | 1,105 | 1,177 | 1,164 | 1,205 | 1,258 |
| Operating Profit | 128 | 181 | 170 | 271 | 161 | 182 | 206 | 395 | 327 | 390 | 346 | 375 | 499 |
| OPM % | 12% | 16% | 15% | 19% | 14% | 15% | 16% | 24% | 23% | 25% | 23% | 24% | 28% |
| Other Income + | 7 | 6 | 11 | 24 | 9 | 12 | 7 | 72 | 22 | 28 | 14 | 13 | 20 |
| Interest | 33 | 38 | 38 | 42 | 41 | 45 | 48 | 49 | 44 | 34 | 31 | 34 | 35 |
| Depreciation | 84 | 85 | 87 | 89 | 91 | 91 | 89 | 88 | 94 | 96 | 94 | 95 | 96 |
| Profit before tax | 17 | 63 | 57 | 164 | 39 | 58 | 77 | 330 | 211 | 289 | 234 | 259 | 388 |
| Tax % | 24% | 26% | 25% | 26% | 26% | 27% | 25% | 24% | 25% | 25% | 25% | 26% | 25% |
| Net Profit + | 13 | 47 | 43 | 121 | 29 | 42 | 57 | 252 | 158 | 216 | 175 | 192 | 290 |
| EPS in Rs | 0.24 | 0.87 | 0.79 | 2.25 | 0.53 | 0.79 | 1.06 | 4.67 | 2.93 | 4.00 | 3.24 | 3.55 | 5.37 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS